https://orcid.org/0000-0001-6669-471X
References
- Bourne RRA, Jonas JB, Flaxman SR, et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990–2010. Br J Ophthalmol. 2014;98(5):629–638. doi:10.1136/bjophthalmol-2013-304033
- Maguire MG, Ying G-S; CATT Research Group MD. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897–1908. doi:10.1056/NEJMoa1102673
- Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi:10.1056/NEJMoa054481
- Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57–65.e5. doi:10.1016/j.ophtha.2008.10.018
- Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012;119(6):1175–1183. doi:10.1016/j.ophtha.2011.12.016
- Rofagha S, Bhisitkul RB, Boyer DS, et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120(11):2292–2299. doi:10.1016/j.ophtha.2013.03.046
- Talks J, Daien V, Finger RP, et al. The use of real-world evidence for evaluating anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration. Surv Ophthalmol. 2019;64(5):707–719. doi:10.1016/j.survophthal.2019.02.008
- Excellence NIoHaC. NICE guideline [NG82]. Age-related macular degeneration; 2018. Available from: https://www.nice.org.uk/guidance/ng82. Accessed December 16, 2020.
- Murdoch IE, Morris SS, Cousens SN. People and eyes: statistical approaches in ophthalmology. Br J Ophthalmol. 1998;82(8):971–973. doi:10.1136/bjo.82.8.971
- Gillies M, Arnold J, Bhandari S, et al. Ten-year treatment outcomes of neovascular age-related macular degeneration from two regions. Am J Ophthalmol. 2020;210:116–124. doi:10.1016/j.ajo.2019.10.007
- Brynskov T, Munch IC, Larsen TM, et al. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration. Acta Ophthalmol. 2020. doi:10.1111/aos.14183
- Chandra S, Arpa C, Menon D, et al. Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration. Eye. 2020. doi:10.1038/s41433-020-0764-9
- Beck RW, Maguire MG, Bressler NM, Glassman AR, Lindblad AS, Ferris FL. Visual acuity as an outcome measure in clinical trials of retinal diseases. Ophthalmology. 2007;114:1804–1809. doi:10.1016/j.ophtha.2007.06.047
- Arpa C, Khalid H, Chandra S, et al. Ten- year survival trends of neovascular age-related macular degeneration at first presentation. Br J Ophthalmol. 2020. doi:10.1136/bjophthalmol-2020-317161.
- Excellence NIoHaC. NICE guideline [TA155].Ranibizumab and Pegatinib for the treatment of age-related macular degeneration; 2008. National Institute of Health and Care Excellence UK. Available from: www.nice.org.uk/guidance/ta155. Accessed December 16, 2020.
- Excellence NIoHaC. NICE guideline [TA294]. Aflibercept solution for injection for treating wet age-related macular degeneration; 2013. National Institute of Health and Care Excellence UK. Available from: www.nice.org.uk/guidance/ta294. Accessed December 16, 2020.
- Heir JS, Brown DM, Chong V, et al. Intravitreal Aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–2548. doi:10.1016/j.ophtha.2012.09.006
- Ciulla TA, Hussain RM, Pollack JS, et al. Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration in patients: a real-world analysis of 49, 485 eyes. Ophthalmol Retina. 2020;4(1):19–30. doi:10.1016/j.oret.2019.05.017